Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Current Assets (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Current Assets data on record, last reported at $484.7 million in Q1 2026.

  • On a quarterly basis, Current Assets rose 66.58% to $484.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $484.7 million, a 66.58% increase, with the full-year FY2025 number at $498.6 million, up 60.93% from a year prior.
  • Current Assets reached $484.7 million in Q1 2026 per RAPP's latest filing, down from $498.6 million in the prior quarter.
  • Over the last five years, Current Assets for RAPP hit a ceiling of $520.7 million in Q3 2025 and a floor of $150.9 million in Q4 2023.
  • A 4-year average of $354.7 million and a median of $325.9 million in 2024 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: surged 105.34% in 2024, then dropped 20.67% in 2025.
  • Tracing RAPP's Current Assets over 4 years: stood at $150.9 million in 2023, then surged by 105.34% to $309.8 million in 2024, then skyrocketed by 60.93% to $498.6 million in 2025, then decreased by 2.78% to $484.7 million in 2026.
  • Business Quant data shows Current Assets for RAPP at $484.7 million in Q1 2026, $498.6 million in Q4 2025, and $520.7 million in Q3 2025.